Oncolytics announces completion of enrollment in Phase II Reolysin study Oncolytics Biotech announced that enrollment has been completed in a randomized Phase II study of Reolysin in patients with recurrent or metastatic castration resistant prostate cancer. The trial is being sponsored and conducted by the NCIC Clinical Trials Group at Queen's University in Kingston, Ontario. The study is an open-label, randomized, non-blinded, Phase II clinical study of Reolysin given in combination with docetaxel versus docetaxel alone. Approximately 40 response evaluable patients were enrolled in each arm. Although accrual is complete, patient follow-up will continue until planned analyses have been conducted.